Patients with Difficult-to-Treat Depression Do not Exhibit an Increased Frequency of CYP2D6 Allele Duplication

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacopsychiatry

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0033-1343397PMID 23737191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

  2014cited by this paper
• Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population

  2011cited by this paper
• Antidepressant-Resistant Depression and Antidepressant-Associated Suicidal Behaviour: The Role of Underlying Bipolarity

  2011cited by this paper
• Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19

  2011cited by this paper
• Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

  2011cited by this paper
• Add-on Quetiapine for Difficult to Treat Bipolar Depression

  2010cited by this paper
• Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator

  2010cited by this paper
• Therapieresistente Depressionen

  2009cited by this paper
• Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

  2009cited by this paper
• The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

  2009cited by this paper
• DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping

  2009cited by this paper
• Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s.

  2008cited by this paper
• Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.

  2008cited by this paper
• Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

  2007cited by this paper
• The STAR*D project results: A comprehensive review of findings

  2007cited by this paper
• Treatment-resistant depression.

  2006cited by this paper
• Pharmacologic management of difficult-to-treat depression in clinical practice.

  2005cited by this paper
• Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.

  2005cited by this paper
• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

  2005cited by this paper
• The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in Man

  2004cited by this paper
• CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study

  2004cited by this paper
• Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

  2003cited by this paper
• Prevalence and comorbidity of affective disorders in persons making suicide attempts in Hungary: importance of the first depressive episodes and of bipolar II diagnoses.

  2003cited by this paper
• New approaches to managing difficult-to-treat depressions.

  2003cited by this paper
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  2003cited by this paper
• "Difficult-to-treat depression".

  2003cited by this paper
• Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

  2002cited by this paper
• The impact of treatment-resistant depression on health care utilization and costs.

  2002cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• The burden of disease for treatment-resistant depression.

  2001cited by this paper
• Clinical features of treatment-resistant depression.

  2001cited by this paper
• O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants

  1999cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.

  1998cited by this paper
• Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

  1997cited by this paper
• Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.

  1996cited by this paper
• Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

  1993cited by this paper

• The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders

  2018cites this paper
• Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies

  2016cites this paper
• CYP2D6 Metabolizer Phenotypes in Patients Undergoing ECT After Antidepressant Therapy

  2016cites this paper
• Genomic Studies of Treatment Resistance in Major Depressive Disorder

  2016cites this paper
• Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy

  2015cites this paper
• The role of clinical pharmacology and pharmacogenetics in electroconvulsive therapy : from safety to efficacy

  2015cites this paper